NeoGenomics, Inc. (NEO) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-02-17

How it makes money

NeoGenomics earns revenue by delivering oncology diagnostic testing to clinical healthcare providers and offering research support services to biopharmaceutical companies.

The company operates diagnostic testing laboratories focused on cancer. It generates revenue by performing specialized testing services—such as cytogenetics, flow cytometry, molecular testing, and molecular residual disease assays—for community oncologists, pathologists, and hospitals.

In addition to clinical diagnostics, the business earns income from biopharmaceutical clients by providing laboratory testing, biomarker analysis, and data generation for sponsor-led clinical trials.

What protects it: the moat

The company relies on an expansive oncology test menu, rapid sample processing times, and specialized clinical support to retain healthcare clients.

Management claims that NeoGenomics protects its market position through an exclusive focus on cancer diagnostics, offering specialized testing technologies like next-generation sequencing and digital imaging.

The company also emphasizes broad service capabilities, rapid turnaround times, and direct consultative support from medical experts to maintain relationships with community hospitals and oncology practices.

What growth costs

NeoGenomics reinvests capital into genetic test development, laboratory automation, information technology systems, and strategic business acquisitions.

To sustain growth, the company makes investments in developing new genetic tests, expanding next-generation sequencing capabilities, and advancing molecular residual disease testing.

Capital is also directed toward upgrading laboratory information management systems and automating workflows to improve operational efficiency and reduce the cost of testing.

What could damage it

Regulatory changes requiring FDA medical device approval for laboratory-developed tests could impose costly clinical trial burdens and impair testing commercialization.

NeoGenomics relies on developing and performing specialized laboratory tests for cancer diagnosis and treatment monitoring. If regulatory authorities classify these laboratory-developed tests as medical devices, the company would be forced to conduct expensive clinical trials and seek formal regulatory approvals before offering them.

This added regulatory burden would delay new test introductions, substantially increase compliance expenses, and directly impair the company's ability to commercialize its diagnostic capabilities.

About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Other companies in Diagnostics & Research